Results 1 to 10 of about 10,088 (191)

Rifaximin alleviates irinotecan-induced diarrhea in mice model

open access: yesAnnals of Medicine
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang   +9 more
doaj   +1 more source

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients

open access: yesAntibiotics, 2020
Rifaximin is a poorly absorbable antibiotic against hepatic encephalopathy (HE). This observational study aimed to elucidate the effect of rifaximin on intestinal permeability and gut microbiota in patients with decompensated cirrhosis.
Kosuke Kaji   +15 more
doaj   +1 more source

Network Meta‐Analysis: Treatments for Acute Alcohol‐Associated Hepatitis

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background Alcohol‐related hepatitis (AH) is an acute form of liver disease with a high short‐term mortality. A variety of treatments have been explored in randomised studies. Recent consensus on study outcomes has identified 90‐day survival as the primary outcome metric.
Charles Gallaher   +7 more
wiley   +1 more source

Increased risk of antimicrobial resistance in patients with cirrhosis and hepatic encephalopathy using rifaximin

open access: yesNature Communications
Rifaximin, a non-absorbable antibiotic used in managing recurrent hepatic encephalopathy (HE), has traditionally been considered low risk for inducing resistance.
Cheng-Hao Kuo   +6 more
doaj   +1 more source

Citicoline versus Rifaximin in Prevention of Recurrence of Hepatic Encephalopathy [PDF]

open access: yesAfro-Egyptian Journal of Infectious and Endemic Diseases
Background and study aims: Hepatic encephalopathy (HE) is a major neuropsychiatric complication of liver cirrhosis. Recurrent episodes significantly impair quality of life and increase hospitalization and mortality risks.
Mohammed Hussien Ahmed   +5 more
doaj   +1 more source

Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 871-889, October 2026.
The intestinal microbiome is a key regulator of immune homeostasis, metabolism, and epithelial barrier integrity. In patients with malignant hematological diseases, particularly those undergoing hematopoietic stem cell transplantation, microbiome perturbations by reduced diversity, pathobiont expansion, and loss of beneficial metabolites are common as ...
Bálint Gergely Szabó   +7 more
wiley   +1 more source

Rifaximin Improves Visceral Hyperalgesia via TRPV1 by Modulating Intestinal Flora in the Water Avoidance Stressed Rat

open access: yesGastroenterology Research and Practice, 2020
Background. Rifaximin is effective in relieving pain symptoms with IBS patients, although the mechanisms were not clear. The aims of the research were to investigate whether the visceral hyperalgesia was alleviated by rifaximin via TRPV1 channel in rats.
Chang-qing Yang   +6 more
doaj   +1 more source

Five‐Year CT‐Based Skeletal Muscle Decline Curves in Cirrhosis According to Liver Functional Reserve and Routinely Available Clinical Factors

open access: yesJGH Open, Volume 10, Issue 10, October 2026.
ABSTRACT Background Sarcopenia is common in cirrhosis and is associated with poor outcomes. We aimed to identify factors associated with longitudinal skeletal muscle loss and to explore estimation of future L3 skeletal muscle index (L3‐SMI) using routinely available clinical variables. Methods This retrospective longitudinal study included 175 patients
Suguru Miida   +14 more
wiley   +1 more source

C-Reactive Protein Levels Predict Improvement in the Liver Functional Reserve by Long-Term Rifaximin Treatment

open access: yesDiseases
Objectives: Rifaximin is a non-absorbable antibiotic that has an efficacy for hepatic encephalopathy (HE). We previously demonstrated that rifaximin improved liver functional reserve, but this was a single-center study with a limited number of cases, and
Kensuke Kitsugi   +9 more
doaj   +1 more source

A Multicenter, Prospective Real‐World Study of Simethicone–Activated Charcoal in Patients With Persistent Dyspeptic Symptoms Despite Acid Suppression (SIMAC Study)

open access: yesJGH Open, Volume 10, Issue 10, October 2026.
ABSTRACT Background Persistent gas‐predominant dyspeptic symptoms affect many patients despite adequate proton pump inhibitor (PPI) therapy, reflecting mechanisms beyond acid secretion. We evaluated the real‐world effectiveness and safety of simethicone (80 mg) plus activated charcoal (250 mg) in adults with persistent symptoms despite prior PPI ...
Ashish Kumar   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy